Showing results (231-240 of 241) with videos related to

Sort By:
Pageof 25
Journal of the National Comprehensive Cancer Network : JNCCN|October 22, 2013
Ovarian cancer, version 2.2013Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
Gynecologic Oncology|January 26, 2024
Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypesStuart S Winkler, Chunqiao Tian, Yovanni Casablanca, et al.
Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyMatthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Gynecologic Oncology|April 9, 2024
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trialsZachary A Kopelman, Chunqiao Tian, Jordyn Tumas, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
Pageof 25